Multinational cost‐effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
Abstract Aims Heart failure is a chronic progressive condition, with considerable burden on patients' quality of life and economic burden for the healthcare systems. Before the approval of empagliflozin, there were no proven effective treatments for patients with heart failure with left ventricular...
Сохранить в:
| Главные авторы: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2023-12-01
|
| Серии: | ESC Heart Failure |
| Предметы: | |
| Online-ссылка: | https://doi.org/10.1002/ehf2.14470 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|